Resumen de Investigación
Analyzed using Evidence Intelligence™

Automated insulin delivery reduces hypoglycemia risk

Última actualización 9 de septiembre de 2026

Key finding

AID resulted in significant reduction of TBR by -3.7% (95% CI -4.8, -2.6), P < 0.001.

This study evaluated the impact of automated insulin delivery on hypoglycemia risk in adults with Type 1 diabetes, finding significant reductions in time below range.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Risk of bias

Some Concerns

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study evaluated the impact of automated insulin delivery on hypoglycemia risk in adults with Type 1 diabetes, finding significant reductions in time below range.

Clinical relevance

These findings are clinically significant as they suggest that automated insulin delivery systems can enhance glucose control and reduce the risk of hypoglycemia, which is a common and dangerous complication in diabetes management. Improved management of blood sugar levels can lead to better overall health outcomes for patients.

Keep in mind

The study did not test time with glucose levels <54 mg/dL. Mean sensor glucose readings were similar, limiting differentiation between interventions. The generalizability of findings may be limited to the specific population studied.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Eric R, Michael J, Orianne V, et al. Automated Insulin Delivery Reduces Hypoglycemia Risk in Adults with Type 1 Diabetes. Diabetes Care. 2023;46(12):2180-2187. doi:10.2337/dc23-0685

Efectos Principales

AID reduced time below range (TBR) by 3.7% (P < 0.001).

AID increased time in target range (TIR) by 8.6% (P < 0.001).

AID decreased time above range (TAR) by 5.3% (P = 0.004).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Hybrid closed-loop system, Insulin pump and Mean sensor glucose, Time above range, Time below range, and 2 more.

Primary intervention

Hybrid closed-loop system

Primary outcomes

  • Mean sensor glucose
  • Time above range
  • Time below range

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

10
Evidence pairs
10
Relationships
4
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

4

Related topics

10

Evidence pairs

1037

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 10 evidence relationships
  • Includes primary outcome data
  • Linked to 4 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

Insulin Delivery Systems and CGM Time in Range

Evidencia relacionada

Tema de evidencia

Diabetes Technology

Guardar evidencia

Tema de evidencia

Hypoglycemia

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

Mean sensor glucose

Hybrid closed-loop system → Mean sensor glucose

Hybrid closed-loop system → Mean sensor glucose

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
75
Positive
ConsistencyScore™
35
mixed
Estudios de apoyo: Basado en 2 estudios
Add to Evidence Tracker

Time above range

Hybrid closed-loop system → Time above range

Hybrid closed-loop system → Time above range

Evidence Intelligence™
EvidenceScore™
79
Strong
ImpactScore™
88
Very Positive
ConsistencyScore™
100
consistent
Estudios de apoyo: Basado en 4 estudios
Add to Evidence Tracker

Time below range

Hybrid closed-loop system → Time below range

Hybrid closed-loop system → Time below range

Evidence Intelligence™
EvidenceScore™
78
Strong
ImpactScore™
83
Positive
ConsistencyScore™
67
generally_consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence Tracker

Time in range

Hybrid closed-loop system → Time in range

Hybrid closed-loop system → Time in range

Evidence Intelligence™
EvidenceScore™
88
Strong
ImpactScore™
81
Positive
ConsistencyScore™
71
generally_consistent
Estudios de apoyo: Basado en 21 estudios
Add to Evidence Tracker

Time spent below 54 mg/dL

Hybrid closed-loop system → Time spent below 54 mg/dL

Hybrid closed-loop system → Time spent below 54 mg/dL

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
75
Positive
ConsistencyScore™
35
mixed
Estudios de apoyo: Basado en 2 estudios
Add to Evidence Tracker

Mean sensor glucose

Insulin pump → Mean sensor glucose

Insulin pump → Mean sensor glucose

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
50
Neutral
ConsistencyScore™
35
mixed
Estudios de apoyo: Basado en 2 estudios
Add to Evidence Tracker

Time above range

Insulin pump → Time above range

Insulin pump → Time above range

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
50
Neutral
ConsistencyScore™
35
mixed
Estudios de apoyo: Basado en 2 estudios
Add to Evidence Tracker

Time below range

Insulin pump → Time below range

Insulin pump → Time below range

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
50
Neutral
ConsistencyScore™
35
mixed
Estudios de apoyo: Basado en 2 estudios
Add to Evidence Tracker

Time in range

Insulin pump → Time in range

Insulin pump → Time in range

Evidence Intelligence™
EvidenceScore™
Strong
Score 79 · Based on 3 studies
ImpactScore™
50
Neutral
ConsistencyScore™
67
generally_consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence Tracker

Time spent below 54 mg/dL

Insulin pump → Time spent below 54 mg/dL

Insulin pump → Time spent below 54 mg/dL

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

La Evidencia Sugiere

  • AID significantly reduced TBR by 3.7%, indicating less hypoglycemia risk.
  • AID increased TIR by 8.6%, suggesting better glucose control.
  • AID decreased TAR by 5.3%, showing reduced time spent with high glucose levels.
who this applies

A quién se aplica

  • Adults diagnosed with Type 1 diabetes.
  • Individuals using insulin therapy for glucose management.
keep in mind

Tener en Cuenta

  • Results may not apply to children or adolescents with Type 1 diabetes.
  • The study did not explore long-term effects of AID.
  • Further research is needed to confirm findings in diverse populations.
between the lines

Entre Líneas

  • The study did not test time with glucose levels <54 mg/dL.
  • Mean sensor glucose readings were similar, limiting differentiation between interventions.
  • The generalizability of findings may be limited to the specific population studied.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on Insulin Delivery Systems and CGM Time in Range, Insulin Delivery Systems and CGM Time in Range.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Insulin Delivery Systems improve CGM Time in Range?

Strong Evidence

Insulin Delivery Systems may improve CGM Time in Range.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

  1. 1

    Time in range

    EvidenceScore™ Strong | EvidenceScore™ 87.7 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study

  2. 2

    Time above range

    EvidenceScore™ Strong | EvidenceScore™ 78.6 | strong positive | ConsistencyScore™ Consistent | 1 study

  3. 3

    Time below range

    EvidenceScore™ Strong | EvidenceScore™ 78.3 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study

Why this answer: This answer is based on 38 supporting studies with generally consistent results and a positive effect signal.

38 supporting studies

Does Hybrid closed-loop system improve mean sensor glucose?

Moderate Evidence

Hybrid closed-loop system may improve mean sensor glucose.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

  1. 1

    Mean sensor glucose

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Only one supporting study is available.
1 supporting study

Does Hybrid closed-loop system improve time spent below 54 mg/dl?

Moderate Evidence

Hybrid closed-loop system may improve time spent below 54 mg/dl.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

  1. 1

    Time spent below 54 mg/dL

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Only one supporting study is available.
1 supporting study

Does Insulin pump improve mean sensor glucose?

Moderate Evidence

Current evidence does not show a clear benefit of Insulin pump for mean sensor glucose.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

  1. 1

    Mean sensor glucose

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Only one supporting study is available.
1 supporting study
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.